WOBURN, Mass. , July 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2020 . The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic health

WOBURN, Mass. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) published an infographic on chronic knee pain ( available here ) and provided an update on how Quell technology addresses knee pain. One-quarter of U.S. adults suffer from frequent knee pain, which decreases

WOBURN, Mass. , Aug. 20, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH -funded, multi-site randomized controlled trial (RCT) of the efficacy of transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced

WOBURN, Mass. , Sept. 01, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today reported the publication of a large study demonstrating that DPNCheck effectively determines the severity of diabetic peripheral neuropathy (DPN).  DPNCheck is a widely used point-of-care test that provides

WOBURN, Mass. , Sept. 04, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today reported that it will present a scientific poster at the PAINWeek 2020 Live Virtual Conference to be held September 11 - 13.  PAINWeek is the preferred resource in the U.S.

WOBURN, Mass. , Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office will issue on September 22, 2020 U.S. Patent No. 10,780,269 titled “Apparatus and Method for Relieving Pain Using Transcutaneous Electrical Nerve

WOBURN, Mass. , Sept. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today reported the launch of the Quell Watch App , now available for download from the Apple App store. The Quell Watch app gives a Quell user the ability to control and monitor their pain relief from their Apple

WOBURN, Mass. , Oct. 15, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 third quarter financial results before the opening of the market on October 22, 2020 . The Company will host a conference call at 8:00 a.m., Eastern Time on October 22,

WOBURN, Mass. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2020 . The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic

WOBURN, Mass. , Jan. 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2020 fourth quarter and full year financial results before the opening of the market on January 28, 2021 . The Company will host a conference call at 8:00 a.m., Eastern Time